Yuri Rukazenkov

16.4k total citations · 6 hit papers
55 papers, 4.1k citations indexed

About

Yuri Rukazenkov is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Yuri Rukazenkov has authored 55 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pulmonary and Respiratory Medicine, 49 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Yuri Rukazenkov's work include Lung Cancer Treatments and Mutations (46 papers), Colorectal Cancer Treatments and Studies (21 papers) and Lung Cancer Research Studies (17 papers). Yuri Rukazenkov is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Colorectal Cancer Treatments and Studies (21 papers) and Lung Cancer Research Studies (17 papers). Yuri Rukazenkov collaborates with scholars based in United Kingdom, Japan and South Korea. Yuri Rukazenkov's co-authors include Yi‐Long Wu, James Chih‐Hsin Yang, Kazuhiko Nakagawa, Suresh S. Ramalingam, Tony Mok, Masahiro Fukuoka, Nagahiro Saijo, Sumitra Thongprasert, Georgina Speake and Patrapim Sunpaweravong and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Yuri Rukazenkov

53 papers receiving 4.1k citations

Hit Papers

Biomarker Analyses and Final Overall Survival Results Fro... 2011 2026 2016 2021 2011 2018 2017 2018 2023 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
    2011 1.2k citations Masahiro Fukuoka, Yi‐Long Wu et al. Journal of Clinical Oncology profile →
  2. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
    2018 511 citations Thanyanan Reungwetwattana, Kazuhiko Nakagawa et al. Journal of Clinical Oncology profile →
  3. Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
    2017 380 citations Suresh S. Ramalingam, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  4. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
    2018 269 citations Suresh S. Ramalingam, Yi Cheng et al. Annals of Oncology profile →
  5. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
    2023 263 citations Roy S. Herbst, Thomas John et al. profile →
  6. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
    2023 130 citations Juliann Chmielecki, Jhanelle E. Gray et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuri Rukazenkov United Kingdom 21 3.7k 3.0k 1.0k 945 171 55 4.1k
Tiziana Usari Italy 17 3.5k 1.0× 3.1k 1.0× 1.2k 1.2× 1.0k 1.1× 397 2.3× 51 4.4k
Victoria A. Joshi United States 17 2.1k 0.6× 1.8k 0.6× 1.1k 1.1× 638 0.7× 156 0.9× 29 3.0k
Piotr Serwatowski Germany 15 3.5k 1.0× 4.0k 1.4× 1.0k 1.0× 626 0.7× 182 1.1× 28 5.3k
Yaroslav Shparyk United States 24 2.4k 0.6× 3.0k 1.0× 870 0.9× 965 1.0× 177 1.0× 70 3.9k
Manuel Cobo Spain 30 3.4k 0.9× 3.6k 1.2× 1.3k 1.3× 1.1k 1.2× 313 1.8× 219 5.3k
Janusz Rolski Poland 15 2.8k 0.8× 2.8k 1.0× 763 0.8× 800 0.8× 171 1.0× 45 4.2k
Santiago Viteri Spain 31 2.1k 0.6× 2.1k 0.7× 1.3k 1.3× 903 1.0× 324 1.9× 169 3.4k
Jennifer Tursi Italy 14 2.5k 0.7× 2.1k 0.7× 841 0.8× 681 0.7× 299 1.7× 25 3.2k
Jin‐Ji Yang China 36 3.9k 1.1× 3.5k 1.2× 1.2k 1.2× 1.1k 1.1× 295 1.7× 146 4.9k
Annetta Krebs United States 8 1.9k 0.5× 2.0k 0.7× 723 0.7× 395 0.4× 163 1.0× 8 2.8k

Countries citing papers authored by Yuri Rukazenkov

Since Specialization
Citations

This map shows the geographic impact of Yuri Rukazenkov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuri Rukazenkov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuri Rukazenkov more than expected).

Fields of papers citing papers by Yuri Rukazenkov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuri Rukazenkov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuri Rukazenkov. The network helps show where Yuri Rukazenkov may publish in the future.

Co-authorship network of co-authors of Yuri Rukazenkov

This figure shows the co-authorship network connecting the top 25 collaborators of Yuri Rukazenkov. A scholar is included among the top collaborators of Yuri Rukazenkov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuri Rukazenkov. Yuri Rukazenkov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Blakely, Collin M., Jacqulyne Robichaux, Kyung‐Yul Lee, et al.. (2025). OA02.02 Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC. Journal of Thoracic Oncology. 20(10). S12–S13. 1 indexed citations
2.
Yang, Jincheng, Aarti Sawant‐Basak, A. Todd, et al.. (2025). Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC. Clinical Pharmacology & Therapeutics. 118(5). 1110–1121. 1 indexed citations
3.
Ramalingam, Suresh S., Pasi A. Jänne, Jhanelle E. Gray, et al.. (2025). EGFR mutation testing across the osimertinib clinical program. Lung Cancer. 204. 108549–108549.
4.
John, Thomas, Christian Grohé, Jonathan W. Goldman, et al.. (2024). Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8005–8005. 15 indexed citations
5.
6.
Chmielecki, Juliann, Jhanelle E. Gray, Ying Cheng, et al.. (2023). Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 14(1). 1070–1070. 130 indexed citations breakdown →
7.
Gray, Jhanelle E., Ji‐Youn Han, Xiangning Huang, et al.. (2023). Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non–Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic. Journal of Molecular Diagnostics. 26(1). 73–84. 4 indexed citations
8.
Planchard, David, Michael Boyer, Arunee Dechaphunkul, et al.. (2018). Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes. Annals of Oncology. 29. ix150–ix150. 2 indexed citations
9.
Planchard, David, Michael Boyer, Jin Sun Lee, et al.. (2018). 128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes. Journal of Thoracic Oncology. 13(4). S72–S73. 13 indexed citations
10.
Reungwetwattana, Thanyanan, Kazuhiko Nakagawa, Byoung Chul Cho, et al.. (2018). CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 36(33). 3290–3297. 511 indexed citations breakdown →
11.
Ramalingam, Suresh S., Yi Cheng, C. Zhou, et al.. (2018). Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Annals of Oncology. 29. viii740–viii740. 269 indexed citations breakdown →
12.
13.
Ramalingam, Sundar, Thanyanan Reungwetwattana, Arunee Dechaphunkul, et al.. (2017). Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Annals of Oncology. 28. v635–v635. 20 indexed citations
14.
Ohe, Yuichiro, Suresh S. Ramalingam, Thanyanan Reungwetwattana, et al.. (2017). Osimertinib vs standard of care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA. Annals of Oncology. 28. x125–x125. 1 indexed citations
15.
Soria, J.C., Soo Wan Kim, Yi‐Long Wu, et al.. (2016). Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis. Annals of Oncology. 27. vi416–vi416. 13 indexed citations
16.
17.
Satouchi, Miyako, Lyudmila Bazhenova, T. Hirashima, et al.. (2015). 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies. European Journal of Cancer. 51. S625–S626. 38 indexed citations
18.
Malorni, Luca, Chiara Biagioni, J. Thirlwell, et al.. (2014). Efficacy of Fulvestrant According to Duration and Type of Adjuvant Endocrine Treatment, in Metastatic Breast Cancer Patients Enrolled in the Confirm Trial. Annals of Oncology. 25. i8–i8. 1 indexed citations
19.
Leo, Angelo Di, Guy Jérusalem, Luboš Petruželka, et al.. (2013). Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. JNCI Journal of the National Cancer Institute. 106(1). djt337–djt337. 232 indexed citations
20.
Rukazenkov, Yuri, Georgina Speake, Gayle Marshall, et al.. (2009). Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. Anti-Cancer Drugs. 20(10). 856–866. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tiziana Usari Breakdown of academic impact, for papers by Victoria A. Joshi Breakdown of academic impact, for papers by Piotr Serwatowski Breakdown of academic impact, for papers by Yaroslav Shparyk Breakdown of academic impact, for papers by Manuel Cobo Breakdown of academic impact, for papers by Janusz Rolski Breakdown of academic impact, for papers by Santiago Viteri Breakdown of academic impact, for papers by Jennifer Tursi Breakdown of academic impact, for papers by Jin‐Ji Yang Breakdown of academic impact, for papers by Annetta Krebs
Rankless by CCL
2026